Capricor Therapeutics
The MSAT Associate 2 at Capricor Therapeutics supports cGMP biologics manufacturing operations through scientific problem solving, technical writing, and investigation management. The role involves collaborating with cross-functional teams to ensure compliant and efficient production of cell therapy and exosome-based products, contributing to process improvements and regulatory compliance.
Headquarters
San Diego, California, United States
Company Size
51-200 employees
Founded
2005
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a San Diego–based biotechnology company developing cell- and exosome-based therapeutics for muscular and other select diseases. Its lead candidate, deramiocel (CAP‑1002), is an allogeneic cell therapy currently in Phase 3 clinical development for Duchenne muscular dystrophy. Capricor is also advancing exosome technology as a next‑generation platform, engineering exosomes to deliver nucleic acids and proteins to treat or prevent a variety of diseases. The company focuses on translating these platforms into novel therapeutic and preventive products.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Capricor Therapeutics.
Duchenne trial drug from Capricor slows key task decline 83%
23 hours ago